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Abstract
Objective: This individual patient data (IPD) meta‐analysis aimed to evaluate the effects of
psychosocial interventions (PSI) on quality of life (QoL), emotional function (EF), and social
function (SF) in patients with cancer, and to study moderator effects of demographic, clinical,
personal, and intervention‐related characteristics.
Methods: Relevant studies were identified via literature searches in 4 databases. We pooled
IPD from 22 (n = 4217) of 61 eligible randomized controlled trials. Linear mixed‐effect model
analyses were used to study intervention effects on the post‐intervention values of QoL, EF,
and SF (z‐scores), adjusting for baseline values, age, and cancer type. We studied moderator
effects by testing interactions with the intervention for demographic, clinical, personal, and
intervention‐related characteristics, and conducted subsequent stratified analyses for significant
moderator variables.Results: PSI significantly improved QoL (β = 0.14,95%CI = 0.06;0.21), EF
(β = 0.13,95%CI = 0.05;0.20), and SF (β = 0.10,95%CI = 0.03;0.18). Significant differences in
effects of different types of PSI were found, with largest effects of psychotherapy. The effects
of coping skills training were moderated by age, treatment type, and targeted interventions.
Effects of psychotherapy on EF may be moderated by cancer type, but these analyses were based
on 2 randomized controlled trials with small sample sizes of some cancer types.
Conclusions: PSI significantly improved QoL, EF, and SF, with small overall effects. However,
the effects differed by several demographic, clinical, personal, and intervention‐related
characteristics. Our study highlights the beneficial effects of coping skills training in patients
treated with chemotherapy, the importance of targeted interventions, and the need of developing
interventions tailored to the specific needs of elderly patients.
KEYWORDS
coping skills training, individual patient data meta‐analysis, neoplasm, psychosocial care,
psychotherapy, quality of life
1 | BACKGROUND
Previous systematic reviews and meta‐analyses from randomized
controlled trials (RCTs) have reported that psychosocial interventions
(PSI) significantly reduce psychosocial problems and improve the quality
of life (QoL), emotional function (EF), and social function (SF) of patients
during and after cancer treatment, but effects sizes vary.1-13 Better
insight into intervention moderators can facilitate identifying and subse-
quently targeting subgroups of patients with cancer that respond best
to a particular type of PSI, thereby improving the intervention effects.14
Results from individual RCTs have suggested that younger age,
female gender, lower socio‐economic status, having breast cancer com-
pared with lung cancer, cancer recurrence, lower self‐esteem, higher
depressive symptoms, and lower self‐efficacy moderate the effects of
PSI in patients with cancer.15-19 However, these findings from individ-
ual RCTs should be interpreted with caution as they are generally not
designed and powered to study moderators of intervention effects.20
Additionally, meta‐analyses on aggregate (summary) data from
RCTs have shown that the effects of PSI on psychological well‐being
were larger in patients with older age, male gender, lower income,
and other types of cancer compared with breast cancer.6 Larger
effects have also been reported for patients with higher distress and
lower QoL at baseline, and who attended a psychotherapeutic or
psycho‐educational intervention compared with an information‐only
intervention.1,2,4,5,7,12 However, a meta‐analysis of summary data relies
onmean patient characteristics (eg, themean age of patients or the pro-
portion of women in a study), which does not allow testing of interac-
tions between the intervention and patient‐level characteristics.20
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The use of summary data thereby increases the risk for ecological bias,
which refers to the failure of associations at the study‐level to correctly
reflect associations at the patient‐level caused by confounding factors
across trials.21 Moderator effects found in aggregate data meta‐analy-
ses should therefore be interpreted with caution.
A meta‐analysis of individual patient data (IPD) involves obtaining
and then synthesizing the raw IPD from multiple related studies,22 and
has the advantage to test interactions between interventions and
patient‐level characteristics using the large number of raw data points,
conducting subsequent stratified analyses, and standardized analytic
techniques across the included studies.23,24
The current IPD meta‐analysis is part of the Predicting OptimaL cAn-
cer RehabIlitation and Supportive care (POLARIS) study.25 The aims were
to evaluate the effects of PSI on QoL, EF, and SF in patients with cancer,
and to identify for the first time demographic, clinical, personal, and inter-
vention‐relatedmoderators of intervention effects with IPDmeta‐analysis.
2 | METHODS
2.1 | Identification and inclusion of studies
Detailed descriptions of the design, procedures, and search strategies
of the POLARIS study have been published previously.25 Briefly, rele-
vant published and unpublished studies (eg, study protocol papers)
were identified via systematic searches in 4 electronic databases
(PubMed, EMBASE, PsycINFO, and CINAHL), reference checking of
systematic reviews, meta‐analyses, and personal communication with
collaborators, colleagues, and other experts in the field.25 The original
search was conducted in September 2012.25 In case an identified study
was not yet published, we maintained contact about the study comple-
tion date, to allow inclusion at a later stage during the data collection
process of approximately 3 years. POLARIS included RCTs that evalu-
ated the effects of physical activity interventions and/or PSI on QoL
compared with a wait‐list, usual care, or attention control group in adult
patients with cancer.25 The effects of physical activity interventions on
QoL and physical function have been reported elsewhere.26
We used Cunningham's hierarchic classification to distinguish 5
types of heterogenetic PSI, based on the degree of psychological
change that the different interventions aim to promote in patients with
cancer: (1) information provision, ie, interventions aiming to increase a
patient's knowledge of cancer and/or its treatments, side effects, and
consequences; (2) support, ie, interventions intended to help patients
to cope with the implications of cancer and its treatment, eg, express
associated emotions, diminish a sense of isolation, identify unmet
needs, take some control over events, deal with family members and
health care personnel, and accept losses and changed roles; (3) coping
skills training (CST), ie, interventions targeted at attaining new cogni-
tive‐behavioral skills such as relaxation, mental imaging, thought and
affect management, and activity planning; (4) psychotherapy, ie, inter-
ventions delivered by an appropriately trained professional which aim
to achieve a more fundamental psychological change to increase self‐
understanding via, for example, psychodynamic therapy, and support-
ive‐therapeutic approaches; and (5) spiritual or existential therapy, ie,
interventions promoting experiential awareness of a transcendent
order or power, some sense of belonging to a meaningful universe
including mediation and prayer (where meaningful to the patient),
appropriate reading, discussion, and reflection around spiritual topics.27
For the current IPD meta‐analysis, RCTs on PSI that fit in the first 4
categories were included. Although we acknowledge the potential
importance of the fifth category, we excluded RCTs focusing on PSI in
this category, because of the heterogeneity of RCTs on PSI in this
category (eg, spiritual or existential therapy, including meditation and
mindfulness). At this point, we also excluded interventions such as yoga
and pain management, as well as diet or multimodal lifestyle interven-
tions (for example physical activity and diet combined), to reduce hetero-
geneity, and to keep the number of datasets to be retrieved manageable.
Based on the description of the intervention provided in the original
studies, 2 authors (JK + IVdL) independently classified the type of
intervention. Disagreements (9%) were resolved by discussion. All PIs
of original studies approved the categorization. The study protocol was
registered in PROSPERO in February 2013 (CRD42013003805).25
A letter of invitation to join the POLARIS consortium and share
data was sent to the principal investigator (PI) of eligible RCTs. In case
of no response, we sent reminders or contacted another PI on the same
study. After PIs expressed interest in data sharing, they were requested
to sign a data sharing agreement stating that they agreed with the
POLARIS policy document and were willing to share anonymized data
of study participants who were randomized. The data could be supplied
in various formats and were checked for completeness, improbable
values, consistency with published articles, and missing items. Subse-
quently, data sets were imported in the POLARIS database where they
were re‐coded according to standardized protocols and harmonized.25
2.2 | Representativeness of included studies
To examine whether the included RCTs were a representative sample
of all eligible RCTs, we compared pooled effect sizes of RCTs included
with those not included. For this purpose, we updated the original
search in October 2017 to also include studies that were published
recently. Effect sizes per RCT were calculated by subtracting the
published average post‐intervention value of QoL, EF, or SF of the con-
trol group from that of the intervention group and dividing the result by
the pooled standard deviation. We adjusted effect sizes for small sam-
ples as suggested by Hedges and Olkin.28 Effect sizes (Hedges'g) were
pooled with a random effects model and differences in effects between
studies providing data and those that did not were examined using
Comprehensive Meta‐analysis software (version 2.2.064).
We evaluated publication bias for all eligible studies and for studies
providing data by inspecting the funnel plot and by the Duval and
Tweedie's trim and fill procedure.29,30 The procedure provides esti-
mates of the number of missing studies and the effect size after the
publication bias has been taken into account. The Egger's test was used
to test whether the bias captured by the funnel plot was significant.
2.3 | Data extraction and quality assessment of
included studies
Two independent researchers (JK +MS) extracted study characteristics
and rated the quality of included studies from the published papers.We
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used the recommended “risk of bias” assessment tool of the Cochrane
Collaboration31 to grade the quality as high (“+”), low (“−”), or unclear
(?) on the following aspects: random sequence generation (high quality
if a random assignment was used), allocation concealment (high quality
in case of central, computerized allocation or sequentially numbered
sealed envelopes), incomplete outcome (high quality if intention‐
to‐treat analyses were performed, and less than 10% of the outcome
data were missing or adequate imputation techniques were used), and
incomplete reporting (high quality if all pre‐specified outcomes were
reported such that they could be entered in an summary data meta‐
analysis). In addition, we included ratings of adherence (high quality if
≥80% of patients had high attendance, defined as ≥80% of sessions
attended) and contamination (high quality if no or limited adoption
(<20%) of the intervention in the control group) as other potential
sources of bias. Items related to blinding were omitted because blinding
of patients and personnel is difficult in case of a PSI. Also, the rating of
blinding of outcome assessors was excluded because QoL, EF, and SF
were assessed using patient‐reported outcomes (PROs). Quality
assessment of both reviewers were compared, and disagreements were
resolved by discussion and consulting a third researcher (LB).
2.4 | Outcome variables
QoL, EF, and SF were assessed with PROs (Table S2). In the present
paper, we used baseline (pre‐intervention) and immediate or closest to
post‐intervention values of the outcomes. Although we acknowledge
the importance of long‐term intervention effects, this paper focuses on
direct (short‐term) effects of the intervention, because follow‐up data
was provided for only half of the studies which also used different
follow‐up durations. To allow pooling of the different PROs, we recoded
the individual scores into z‐scores by subtracting the mean score at
baseline from the individual score, then dividing the result by the mean
standard deviation at baseline. Subsequently, the pooled z‐scores were
used for further analyses. If studies used both a cancer‐specific and a
generic QoL PRO, data from the cancer‐specific PRO were used.
2.5 | Possible moderators
The potential moderators tested in this IPD meta‐analysis were identi-
fied from previous original RCTs or meta‐analyses.1,2,6,7,16,19,32,33
Potential demographic moderators included age, sex, marital status,
and education level. We dichotomized marital status into single and/or
living alone versus married and/or living with partner. As a
consequence of different coding schemes used in the original RCTs,
education level was dichotomized into low‐medium (primary or
secondary school, and lower or secondary vocational education) or
high (higher vocational, college, or university education).
Potential clinical moderators included type of cancer, type of
treatment, and the presence of distant metastases. The type of cancer
was categorized into breast, male genitourinary, gastrointestinal,
hematological, gynecological, respiratory tract, and other types. We
also checked moderator effects of breast cancer versus other types
of cancer. Treatment with surgery, chemotherapy, radiotherapy, or
hormone therapy were each dichotomised into previous or current
treatment versus no such treatment.
Personal moderators included baseline values of QoL, EF, and
SF (z‐scores).
Intervention type was categorized into information, support, CST,
or psychotherapy, according to the classification model of Cunningham
et al.27 Timing of intervention delivery was categorized into pre‐ anti‐
cancer treatment, during treatment, post‐treatment, and end‐of‐life.34
As studies on interventions delivering PSI pre‐treatment and during
end‐of‐life were not available, and only 1 study delivered PSI both
pre‐and post‐treatment, we tested differences in intervention effects
between those delivered during and post‐treatment. As hormone ther-
apy for breast cancer may continue for several years post‐treatment,
we considered women on hormone therapy who completed other
primary cancer treatments as being post‐treatment. Men receiving
androgen deprivation therapy for prostate cancer were considered
as being during treatment. Intervention duration was dichotomized
based on the median (≤12 weeks; >12 weeks). Interventions targeting
patients with distress (eg, depression, fatigue, cognitive problems,
symptoms) were dichotomized into yes or no.
2.6 | Statistical analysis
We conducted 1‐step IPD meta‐analyses to study the effects and
moderators of PSI on QoL, EF, and SF. The effects were evaluated by
regressing the post‐intervention value (z‐score) of the outcome onto
the intervention using linear mixed model analyses with a 2‐level struc-
ture (patients as level one and study as level 2) to take into account the
clustering of patientswithin studies by using a random intercept on study
level. The baseline value of the outcome (z‐score), age and cancer type
were included in the model as covariates. The residuals of the models
were distributed normally. Moderators of the intervention effects were
examined by adding the moderator and its interaction term with the
intervention into the regression model, for each moderator separately.
To reduce ecological bias for patient‐level interactions, we separated
within‐trial interaction from between‐trial interaction by centering the
individual value of the covariate around the mean study value of that
covariate.24 In case a RCT had 3 study arms with different study‐level
moderators across study arms, interaction testing for a study‐level
moderator was not possible. Therefore, in those situations, we tested
differences between subgroups using dummy variables.
If the likelihood ratio test of the model with and without interac-
tion term was significant (P < 0.05), strata were built, and the modera-
tor analyses were repeated in the strata that included data from more
than 1 RCT. Because type of intervention was the most significant
moderator, we re‐examined the other potential moderators of
intervention effects within the strata based on type of intervention
(CST and psychotherapy). Because the majority of patients were
women with breast cancer that followed CST, we performed a sensitiv-
ity analysis in this subgroup of patients.
Regression coefficients and 95% confidence intervals (CI) were
reported, which represent the between group difference in z‐scores
of QoL, EF, and SF, and correspond to a Cohen's d effect size.
According to Cohen,35 d = 0.2 was considered small, d = 0.5 medium,
and d = 0.8 large, respectively. The statistical analyses were conducted
in SPSS 22.0 (IBM Corp. Released 2013. IBM SPSS Statistics for
Windows, Version 22.0. Armonk, NY: IBM Corp.) and RStudio.36
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3 | RESULTS
3.1 | Characteristics of studies and patients
Of the 136 RCTs that met the inclusion criteria for the POLARIS study
in the original search, 59 RCTs evaluated the effects of PSI, and 2
RCTs37,38 that evaluated the effects of physical activity combined
with PSI also included a third study arm with PSI only (Figure 1). PIs
of 22 of the 61 eligible RCTs (response 36%)37,39-59 shared their data.
In 1 RCT focusing on hematological cancer,41 we excluded patients
who followed watchful waiting only (n = 23), as they did not fit into
one of the intervention categories. In 1 RCT that included patients
with mixed cancer types,50 we excluded patients with gastrointestinal
cancer as they received PSI combined with nutritional support
(n = 140). The final dataset included 4217 patients with cancer of
whom 2215 were randomly allocated to the intervention and 2002
to the control group.
In total, 86% of the included RCTs reported random sequence
generation, 73% reported adequate allocation concealment, 77%
had adequate completeness of outcome data, 82% had complete
outcome reporting, 41% described adequate intervention adherence,
and 18% provided information on contamination (Table S1).
The mean age of participants was 56.0 (standard deviation = 11.4)
years, 65% were female, 70% were married and/or lived with a partner,
33% were highly educated, 52% were diagnosed with breast cancer,
and 9% had a distant metastatic disease at baseline (Table S2). Nine-
teen37,39-42,44-50,52-57,59 RCTs evaluated the effects of CST, two43,58
evaluated the effects of psychotherapy, and one51 evaluated informa-
tion only, 17 were conducted post‐cancer treatment, and 8 RCTs
targeted patients with distress (Table S2).
3.2 | Representativeness of included studies
The updated search yielded 38 additional RCTs. Of the 99 eligible
RCTs, 50 reported summary data on QoL, 47 on EF, and 39 on SF.
Of the 22 RCTs included in the IPD meta‐analyses, 10 published
summary data on QoL, 13 on EF, and 8 on SF. We found no
significant differences in effects on QoL (P = 0.10), EF (P = 0.47), and
SF (P = 0.66) between RCTs of which IPD were shared (QoL:
β = 0.10,95%CI = −0.03;0.24, EF: β = 0.13,95%CI = 0.02;0.25, SF:
β = 0.12,95%CI = −0.03;0.27) and those of which IPD were not shared
(QoL: β = 0.25,95%CI = 0.14;0.36, EF: β = 0.19,95%CI = 0.08;0.31, SF:
β = 0.16,95%CI = 0.05;0.27) (Table S3).
The Eggers test was not statistically significant for all eligible and
RCTs included reporting on QoL, EF, and SF, suggesting no evidence
for publication bias.
3.3 | Effects and moderators of PSI on QoL EF and SF
PSI significantly improved QoL (β = 0.14,95%CI = 0.06;0.21), EF
(β = 0.13,95%CI = 0.05;0.20), and SF (β = 0.10,95%CI = 0.03;0.18), see
Table 1 and Figure S1. Intervention effects on QoL (P = 0.05), EF
(P < 0.01), and SF (P = 0.05) were significantly larger for younger patients.
Intervention effects on EF (P = 0.03) were larger for patients who were
single and/or living alone (β = 0.29,95%CI = 0.18;0.40) compared with
married and/or living with partner (β = 0.09,95%CI = 0.03;0.15). Effects
on EF differed by cancer type (P = 0.02). Effects on QoL (P = 0.01) and
EF (P = 0.03) were larger for patients who were treated with chemother-
apy. Intervention effects on EF were significantly larger for patients who
did not receive radiotherapy (P = 0.05). Intervention effects on EF
(P = 0.02) were larger for patients with lower EF at baseline. Type of
PSI (P ≤ 0.01) significantly moderated the effects on QoL, EF, and SF,
with largest effects for psychotherapy (QoL: β = 0.32,95%CI = 0.12;0.51,
EF: β = 0.31,95%CI = 0.10;0.53, SF: β = 0.38,95%CI = 0.16;0.61).
Intervention effects on QoL (P < 0.01), EF (P = 0.01), and SF (P < 0.01)
were significantly larger in studies that specifically targeted patients
with distress.
3.4 | Stratified analyses per intervention type
3.4.1 | Effects and moderators of coping skills training
(19 RCTs)
CST significantly improved QoL (β = 0.11,95%CI = 0.03;0.20), EF
(β = 0.10,95% CI = 0.02;0.18), and SF (β = 0.09,95%CI = 0.04;0.15), see
Table 2. Patients who were younger had larger effects of CST on EF
(P = 0.01) and SF (P = 0.03). Patients treated with chemotherapy had
larger CST effects on QoL and EF (P = 0.01). Patients treated with
surgery had larger effects on SF (P = 0.04). Effects on SF was also larger
in women with breast cancer who did not receive hormone therapy
(P = 0.01). Effects on QoL (P < 0.01) were larger in studies that targeted
patients with distress. Sensitivity analyses among patients with breast
cancer (n = 1753) showed larger CST effects on EF (P = 0.03) in patients
treated with chemotherapy.
3.4.2 | Effects and moderators of psychotherapy (2 RCTs)
Psychotherapy significantly improvedQoL (β=0.45,95%CI=0.15;0.75),
EF (β = 0.36,95%CI = 0.06;0.66), and SF (β = 0.34,95%CI = 0.07;0.62),
see Table 3. Type of cancer moderated the intervention effects of
psychotherapy on EF (P = 0.02). Intervention effects on EF were
significant for patients with breast (β = 0.46,95%CI = 0.06;0.87) and
hematological cancer (β = 1.11,95%CI = 0.34;1.87).
4 | DISCUSSION
This IPD meta‐analysis of 22 RCTs, including 4217 patients with
cancer, showed that PSI significantly improved QoL, EF, and SF, with
small overall effects, both during and after treatment. The present
IPD meta‐analysis enabled the testing of potential moderators of
intervention effects using interaction tests in a large sample. In the
current sample, of which half of the population was diagnosed with
breast cancer and one third with genitourinary cancer, we found
significant differences in effects of different types of PSI, with largest
effects of psychotherapy in comparison with CST and providing
information. The effects of CST were moderated by age, treatment
type, and by targeted interventions. The effects of psychotherapy on
EF may be moderated by cancer type, but these analyses were based
on 2 RCTs with small sample sizes of some cancer types.
Our finding that the effects on QoL, EF, and SF were larger for
psychotherapy than for CST differs from a previous summary data
meta‐analysis that summarized the results of 37 RCTs in a mixed
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TABLE 1 Effects and moderators of psychosocial interventions on quality of life (QoL), emotional function, and social function. Regression coefficients
(β) and 95% confidence intervals (CI) of the intervention effects, and P‐value of the likelihood ratio test of models with and without interactions are
presented
QoL Emotional Function Social Function
β (95% CI) P β (95% CI) P β (95% CI) P
Effect of psychosocial interventions 0.14(0.06;0.21)* 0.13(0.05;0.20)* 0.10(0.03;0.18)*
Age, years 0.05 <0.01 0.05
<50 years 0.25(0.15; 0.36)* 0.22(0.11;0.33)* 0.24(0.14;0.34)*
50–70 years 0.08(0.01;0.14)* 0.11(0.05;0.17)* 0.06(−0.00;0.12)
≥70 years 0.07(−0.06;0.20) −0.01(−0.14;0.12) 0.03(−0.10;0.15)
Sex (men vs women) 0.15 0.85 0.87
Marital status 0.55 0.03 0.88
Single/ living alone … 0.29(0.18;0.40)* …
Married/ living with partner … 0.09(0.03;0.15)* …
Education level (low‐medium vs high) 0.41 0.66 0.40
Type of cancer 0.35 0.02 0.89
Breast … 0.15(0.08;0.23)* …
Genitourinary … 0.07(−0.00;0.15) …
Hematological … 0.14(−0.11;0.38) …
Gastrointestinal … −0.10(−0.36;0.16) …
Gynecological … 0.27(−0.06;0.60) …
Lung … 0.23(−0.06;0.51) …
Other … −0.66(−1.47;0.16) …
Type of cancer (breast vs other) 0.19 0.97 0.59
Distant metastasis at baseline 0.64 0.60 0.60
Surgery 0.81 0.40 0.08
Chemotherapy 0.01 0.03 0.14
No 0.03(−0.04;0.10) 0.06(−0.01;0.12) …
Yes 0.22(0.15;0.29)* 0.20(0.12;0.27)* …
Radiotherapy 0.80 0.05 0.09
No … 0.16(0.08;0.23)* …
Yes … 0.09(0.02;0.16)* …
Hormone therapy for breast cancer 0.88 0.61 0.06
Hormone therapy for prostate cancer 0.75 0.17 0.66
Baseline value of outcome a 0.40 0.02 0.14
<−0.5 SD … 0.17(0.05;0.29)* …
−0.5 to 0.5 SD … 0.14(0.06;0.23)* …
>0.5 SD … 0.08(0.01;0.15)* …
Type of intervention 0.01 0.01 <0.01
Providing information 0.19(0.03;0.34)* 0.11(−0.06;0.28) 0.06(−0.09;0.22)
Support ‐ ‐ ‐
CST 0.09(0.04;0.15)* 0.10(0.04;0.15)* 0.08(0.03;0.13)*
Psychotherapy 0.32(0.12;0.51)* 0.31(0.10;0.53)* 0.38(0.16;0.61)*
Timing of intervention delivery
(during vs post‐treatment)
0.81 0.31 0.69
Targeted intervention <0.01 0.01 <0.01
No 0.07(0.02;0.12)* 0.09(0.04;0.14)* 0.06(0.01;0.11)*
Yes 0.32(0.20;0.43)* 0.21(0.06;0.35)* 0.26(0.14;0.38)*
Intervention duration (≤12 week vs
>12 weeks)
0.14 0.27 0.26
Abbreviation: SD, standard deviation.
aBaseline QoL as moderator for outcome QoL, baseline emotional function as moderator for outcome emotional function, and baseline social function as
moderator for outcome social function.
*P < 0.05.
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cancer population and reported no difference in effects between
information provision (6 RCTs), support (4 RCTs), CST (20 RCTs), and
psychotherapy (7 RCTs).12 However, our finding should be interpreted
with caution, because we were only able to include 2 RCTs evaluating
psychotherapy interventions, and they were offered to patients with
mixed cancer types43 or metastatic breast cancer.58 These 2 RCTs also
targeted patients with higher levels of depressive symptoms, which
may explain the larger effects of psychotherapy compared with CST.60
The larger effects of CST in younger patients found in the current
IPD meta‐analysis may be explained by the higher psychological
distress and supportive care needs of younger patients in physical,
informational, and emotional domains.61,62 Consequently, CST may
more effectively improve EF and SF for this subgroup of patients. Alter-
natively, older patients with cancer may have specific needs that were
not, or only partly, addressed by CST.61 There is limited knowledge,
however, about the supportive care needs of elderly patients with
cancer, who more often have comorbid conditions.61 Further research
is needed to identify the supportive care needs of elderly patients with
cancer and to develop effective CST targeting this population.
Treatment type was a significant moderator effect of CST, such
that larger effects on QoL and EF were found in patients treated with
chemotherapy, and effects on SF were larger in patients with breast
cancer that did not receive hormone therapy, and in patients who
had surgery. The larger effects of CST in patients treated with chemo-
therapy compared with those who were not may be explained by the
specific side effects of chemotherapy, including fatigue,63 pain,64 and
emotional or cognitive problems,65 which are specifically targeted by
CST. The larger effects in patients who did not receive hormone ther-
apy may also be caused by milder side effects of hormone therapy,
compared with chemotherapy. Additionally, patients with hormone‐
TABLE 2 Effects andmoderators of coping skills training (CST) on quality of life (QoL), emotional function, and social function. Regression coefficients
(β) and 95% confidence intervals (CI) of the intervention effects, and P‐value of the likelihood ratio test of models with and without interactions are
presented
QoL Emotional Function Social Function
β (95% CI) P β (95% CI) P β (95% CI) P
Effect of CST interventions 0.11(0.03;0.20)* 0.10(0.02;0.18)* 0.09(0.04;0.15)*
Age, years 0.11 0.01 0.03
<50 years … 0.19(0.07;0.32)* 0.24(0.12;0.36)*
50–70 years … 0.09(0.02;0.16)* 0.04(−0.03;0.11)
≥70 years … −0.02(−0.16;0.11) 0.03(−0.11;0.17)
Sex (men vs women) 0.08 0.77 0.84
Marital status (single/living alone vs
Married/living with partner)
0.33 0.06 0.68
Education level (low‐medium vs high) 0.74 0.79 0.57
Type of cancer 0.81 0.56 0.27
Type of cancer (breast vs other) 0.39 0.63 0.40
Distant metastasis at baseline 0.58 0.61 0.47
Surgery 0.75 0.53 0.04
No … … −0.03(−0.15;0.09)
Yes … … 0.14(0.07;0.20)*
Chemotherapy 0.01 0.01 0.08
No 0.01(−0.06;0.08) 0.03(−0.04;0.10) …
Yes 0.21(0.13;0.29)* 0.18(0.09;0.27)* …
Radiotherapy 0.89 0.24 0.19
Hormone therapy for breast cancer 0.59 0.42 0.01
No … … 0.23(0.12;0.35)*
Yes … … 0.05(−0.05;0.15)
Hormone therapy for prostate cancer 0.85 0.17 0.63
Baseline value of outcome a 0.83 0.14 0.13
Timing of intervention delivery
(during vs post‐treatment)
0.36 0.76 0.35
Targeted intervention <0.01 0.34 0.18
No 0.06(0.00;0.12)* … …
Yes 0.30(0.16;0.45)* … …
Intervention duration (≤12 week vs
>12 weeks)
0.16 0.27 0.26
Abbreviation: SD, standard deviation.
aBaseline QoL as moderator for outcome QoL, baseline emotional function as moderator for outcome emotional function, and baseline social function as
moderator for outcome social function.
*P < 0.05.
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sensitive tumors generally have a lower risk of disease recurrence than
patients with hormone‐insensitive tumors.66 The larger effects of CST
on SF in patients who had surgery should be interpreted with caution
as this may vary by type of surgery (eg, radical mastectomy versus
breast‐preserving surgery67). Additionally, we used broad categories
of treatment in this heterogeneous group of patients and treatment
combinations and intervention timing may vary. Future studies should
therefore examine moderator effects of cancer treatment within more
homogeneous groups of patients. Our sensitivity analyses in women
with breast cancer showed larger CST effects on EF in those treated
with chemotherapy, emphasizing that CST is particularly beneficial in
women with breast cancer treated with chemotherapy.
We observed a larger effect of CST on QoL in RCTs that specifi-
cally targeted patients with higher levels of distress before the
intervention. This underlines the importance of targeting patients with
distress so that the limited available resources for CST can be targeted
to those who need and benefit most from CST. Unexpectedly, despite
larger effects in targeted studies, no moderator effect of the baseline
value of QoL, EF, and SF was found. Also, previous studies on the
moderator effect of baseline distress were inconsistent.1,5,18,60,68
In the 2 RCTs that studied the effects of psychotherapy, that spe-
cifically targeted patients with distress, we found a significant modera-
tor effect of cancer type. Effects on EF were significant for patients
with breast and hematological cancer. Due to the small sample size of
some cancer types, future studies should confirm whether patients
with different cancer types indeed respond differently to interventions.
4.1 | Strengths and limitations
Strengths of this study include the IPD approach and the large number
of RCTs from multiple countries and the resulting large sample size
that enabled testing of interactions between the intervention and
patient‐level characteristics and conducting subsequent stratified
analyses, as well as the uniform analytical procedures across all studies.
The study also had a number of limitations that should be noted. First,
the pooled RCTs were heterogeneous with respect to type of interven-
tion and cancer. Future studies with more homogeneous patient
samples are needed to investigate potential moderator effects of
PSI‐related characteristics and techniques such as delivery format
(eg, individual, group, or couple therapy), method (eg, face‐to‐face,
telephone, or web‐based), and profession (eg, psychologist versus
nurse). Also, other potential psychosocial moderators of PSI effects
such as coping skills, self‐esteem, and perceived social support were
not explored,19,69 and should therefore be examined in future studies.
Another limitation is the time between the literature search and the
current publication. The collection of IPD from multiple RCTs is very
time consuming, and it took more than 3 years to collect these data,
which is comparable to IPD meta‐analysis in other fields of research.22
TABLE 3 Effects and moderators of psychotherapy interventions on quality of life (QoL), emotional function, and social function. Regression coefficients
(β) and 95% confidence intervals (CI) of the intervention effects, and P‐value of the likelihood ratio test of models with and without interactions are
presented
QoL Emotional Function Social Function
β (95% CI) P β (95% CI) P β (95% CI) P
Effect of psychotherapy 0.45(0.15;0.75)* 0.36(0.06;0.66)* 0.34(0.07;0.62)*
Age, years 0.50 0.22 0.58
Sex (men vs women) 0.54 0.62 0.34
Marital status (single/living alone vs
married/living with partner)
0.68 0.25 0.56
Education level (low‐medium vs high) 0.22 0.14 0.74
Type of cancer 0.07 0.02 0.38
Breast … 0.46(0.06;0.87)* …
Genitourinary … 0.49(−0.04;1.03) …
Hematological … 1.11 (0.34;1.87)* …
Gastrointestinal … −0.70(−1.65;0.24) …
Gynecological … 0.36(−0.02;0.75) …
Lung … ‐ …
Other … −0.86(−2.72;1.01) …
Type of cancer (breast vs other) 0.22 0.49 1.00
Surgery 0.31 0.23 0.19
Chemotherapy 0.64 0.66 0.30
Radiotherapy 0.08 0.09 0.09
Hormone therapy for breast cancer 0.51 0.38 0.78
Baseline value of outcome a 0.74 0.20 0.49
Timing of intervention delivery
(during vs post‐treatment)
0.31 0.23 0.24
Abbreviation: SD, standard deviation.
aBaseline QoL as moderator for outcome QoL, baseline emotional function as moderator for outcome emotional function, and baseline social function as
moderator for outcome social function.
*P < 0.05.
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In addition, during these 3 years, we maintained contact with PIs of
ongoing studies (n = 6) of which protocol papers were identified, and
these were included in the current IPD meta‐analysis. The results of
the moderator analyses, however, are novel and valid. Third, only
36% of the eligible RCTs were included in the IPD meta‐analysis, which
may limit the generalizability of the results.70 However, we found no
differences in effect sizes between RCTs included and those not
included, indicating that the 22 RCTs included in the analyses were a
representative sample of the published studies. Additionally, the
results of the current analyses depend on the studies conducted so
far, thus mainly among patients with breast and genitourinary cancer,
and may therefore not be generalizable to other cancer populations.
Fourth, some biases were present in the included RCTs, with little
information on adherence to the PSI and potential contamination in
the control group. Adherence and contamination may influence the
intervention effect as well. With study quality being a study‐level
characteristic of which the power is determined by the number of stud-
ies, it is difficult to disentangle the impact of study quality versus other
intervention‐related characteristics and techniques on the moderator
effects. Therefore, the quality rating was added to inform the reader
about the overall study quality. Finally, as 11 of the 22 RCTs did not
provide sufficient data at follow‐up or used different follow‐up dura-
tions, we were not able to study the intervention effects at long‐terms.
4.2 | Clinical implications
Our study showed that PSI significantly improves QoL, EF, and SF both
during and post cancer treatment, but the overall effects are small.
Psychotherapy appears to have larger effects compared with CST,
but this conclusion is based on just 2 psychotherapy interventions that
specifically targeted patients with distress. The effects of existing CST
were larger for interventions that were targeted, and in patients who
were younger. Additionally, treatment type moderated the effects of
CST. CST was particularly beneficial in patients treated with chemo-
therapy. Our study highlights the importance of targeted interventions,
and it presents the need of developing interventions tailored to the
specific needs of elderly patients.
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